BioSpace News Archive

AlzeCure Pharma AB announced that an abstract on NeuroRestore ACD856 and its positive effects on brain activity in the MAD clinical trial has been accepted for presentation at the annual Alzheimer’s conference CTAD, Clinical Trials in Alzheimer’s Disease, which this year is being held in San Francisco, November 29 - December 2.

BioMed X announced the launch of their first joint research project with Sanofi.

Koya Medical presented two newly published clinical studies for the treatment of lymphedema and venous disease with its Dayspring® active compression system that showed significant improvements in patient outcomes.

ViewRay, Inc. announced that the findings from the first Phase II prospective international multi-institutional study to deliver ablative doses of radiation to pancreatic cancer patients will be presented at the 64th Annual Meeting of the American Society for Radiation Oncology, being held October 23-26, 2022, at the Henry B. Gonzalez Convention Center in San Antonio.

ANI Pharmaceuticals, Inc. announced that the Company will release its third quarter 2022 financial results on Wednesday, November 9, 2022, prior to market open.

EvolveImmune Therapeutics today announced that new preclinical data highlighting EVOLVE™, the company’s novel costimulatory T cell engager platform, were presented at the American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy.

Zentalis™ Pharmaceuticals, Inc. today announced plans to initiate the first study of its collaboration with Pfizer on Zentalis’ product candidate ZN-c3, a selective Wee1 inhibitor designed to induce synthetic lethality in cancer cells.

DolCas Biotech, LLC has attained two Health Canada natural product licenses, one for its concentrated turmeric extract, Curcugen®, and the other for Ginfort®, a powerful ginger extract in powdered format.

Enveric Biosciences Inc. today announced the nomination of EB-373 as the lead development candidate to emerge from its EVM201 program.

Castle Biosciences, Inc. today announced new data from UTILISE (Clinical Utili ty and Health Outcomes Study), a prospective, multi-center, clinical utility study of DecisionDx®-SCC, designed to capture the real-world impact of DecisionDx-SCC test results on the management of patients with cutaneous squamous cell carcinoma (cSCC) and one or more risk factors.